Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Atherosclerosis: Possible Correlation with Clinical Presentation

Receptor for Advanced Glycation End-products (RAGE) is a multi-ligand receptor ubiquitous present on epithelial, neuronal, vascular and inflammatory cells, usually expressed at low levels in homeostasis and to increased degrees at sites of stress or injury. The aim of the present study was to evaluate sRAGE plasma levels in patients with Acute Coronary Syndrome (ACS) and to assess its diagnostic efficacy in identification of patients with acute events. Plasma levels of sRAGE were determined in 860 patients with Coronary Artery Disease (CAD): 530 patients presented stable angina and 330 were observed during acute ischemic event (147 with unstable angina and 183 with myocardial infarction). sRAGE plasma levels were significantly lower in patients with ACS than in patients with stable angina: [median 584 pg/mL (IQR: 266–851 pg/mL) in MI patients, median 769 pg/mL (IQR: 394–987 pg/mL) in patients with unstable angina, median 834 pg/mL (IQR 630–1005 pg/mL) in patients with stable angina;P<0.001]. sRAGE levels did not differ among ACS patients stratified by the extent of coronary artery disease. In conclusion, this study confirm the role of sRAGE in activation and progression of inflammatory process and suggests the possibility that sRAGE can be considered an indicator of destabilization of vulnerable plaque.

Download Full-text

Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/01.atv.0000160342.20342.00 ◽

2005 ◽

Vol 25 (5) ◽

pp. 1032-1037 ◽

Cited By ~ 261

Author(s):

Colomba Falcone ◽

Enzo Emanuele ◽

Angela D’Angelo ◽

Maria P. Buzzi ◽

Chiara Belvito ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Advanced Glycation End Products ◽

Plasma Levels ◽

Soluble Receptor ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

Artery Disease

Download Full-text

The Relationship between Plasma Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease

Disease Markers ◽

10.1155/2019/4528382 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10

Author(s):

Xiangming Wang ◽

Tingting Xu ◽

Deeraj Mungun ◽

Chuanwei Zhou ◽

Zhimin Zha ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Advanced Glycation End Products ◽

Plasma Levels ◽

Control Group ◽

Syntax Score ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

Artery Disease

Background. Inflammation is involved in the development and progression of coronary artery disease (CAD). The role of the receptor for advanced glycation end products (RAGE) in the development of CAD has been recognized. The expression of sRAGE and S100A12 in patients with coronary artery disease from different studies was inconsistent. We attempted to determine the expression of sRAGE and S100A12 and their relationship in the subjects with different severity levels of CAD. Methods. A total of 259 patients undergoing coronary angiography were enrolled from the Department of Geriatric Cardiology in the First Affiliated Hospital of Nanjing Medical University from January 2014 to December 2016. Groups were divided as follows: normal coronary artery (control group), nonobstructive coronary atherosclerosis (<50% stenosis in all coronary vessels, NOCA group), stable angina (SAP group), and acute coronary syndrome (ACS group). During CAG or PCI, peripheral arterial blood was collected from all the patients. Plasma sRAGE and S100A12 levels were measured by ELISA. We calculated the SYNTAX score of each patient with CAD according to the result of CAG. Results. The levels of sRAGE were significantly elevated in the ACS group compared with those in the control group, the NOCA group, and the SAP group. sRAGE levels were similar among the control group, the NOCA group, and the SAP group. Plasma S100A12 levels were significantly higher in the ACS group than in the control group and the NOCA group. Baseline correlations between plasma levels of sRAGE and plasma S100A12 in the ACS group were significant. Plasma sRAGE concentration was increasing in patients with ACS and was significantly positively correlated with the increasing SYNTAX score. ROC curve analysis revealed that the combination of sRAGE and S100A12 had a good performance in the prediction of high-risk CAD patients. Conclusion. The plasma levels of sRAGE and S100A12 can be increased in patients with ACS. The elevated sRAGE concentration may be independently associated with the severity of CAD and the inflammatory process. sRAGE combined with S100A12 may be used as a predictor of severe coronary heart disease.

Download Full-text